|Awarded On||August 24, 2018|
|Title||Targeting the Menopause Transition to Decrease the Risk for Obesity-Associated Postmenopausal Breast Cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University|
|Principal Investigator/Program Director||Erin Giles|
*Pending contract negotiation
Women who are overweight or obese have an increased risk for developing breast cancer after menopause. There are suggestions that an inexpensive, FDA-approved drug used to treat diabetes (called metformin) may also help decrease the risk of developing breast cancer in women who are overweight/obese, or those with diabetes. Using an animal model, we have shown that weight gain during menopause, combined with pre-existing obesity, increases tumor development and growth. We have further shown that treating these same animals with metformin long-term can decrease this breast cancer risk. In this grant, our goal is to determine whether we can specifically target metformin to a narrow window of ti...